康柏西普联合全视网膜光凝治疗糖尿病黄斑水肿的疗效分析

目的:研究康柏西普联合全视网膜光凝(panretinal photocoagulation,PRP)治疗糖尿病黄斑水肿(diabetic macular edema, DME)的疗效及安全性。方法:回顾性分析2016年4月到2018年4月本院接诊的DME患者238例,按照治疗方式的不同将其分成观察组及对照组。对照组采用PRP治疗,观察组则采用抗血管内皮生长因子(vascular endothelial growth factor, VEGF)药物康柏西普联合PRP实施治疗。比较两组患者治疗后的临床效果、手术前后视力和黄斑中心凹厚度的变化及预后情况。结果:治疗后,观察组的治疗效率为94.96%,较对照组(84.87%)显著升高(P0.05)。观察组术后视力明显高于手术前(P0.05),且显著高于对照组(P0.05);观察组术后黄斑中心凹厚度明显小于术前(P0.05),且显著小于对照组。观察组并发症发生率(3.36%)明显低于对照组(10.92%,P0.05)。结论:康柏西普联合PRP治疗DME患者的效果显著优于单用PRP治疗,且安全性更高。

Efficacy of Conbercept Ophthalmic combined with Pan-retinal Photocoagulation in the Treatment of Diabetic Macular Edema

ABSTRACT Objective: To study the efficacy and prognosis of anti vascular endothelial growth factor (VEGF) drug Conbercept Ophthalmic combined with panretinal photocoagulation (PRP)for diabetic macular edema (DME). Methods: 238 cases of DME patients treated in our hospital from April 2016 to April 2018 were selected and divided into the observation group and the control group according to different treatment methods. The control group was treated with PRP, while the observation group was treated with anti-vascular endothelial growth factor (VEGF) drug Conbercept combined with PRP. The clinical effect, visual acuity, macular fovea thickness and prognosis were compared between the two groups. Results: After treatment, the treatment efficiency of the observation group was 94.96%, which was significantly higher than that of the control group (84.87%) (P<0.05). The visual acuity of the observation group was significantly higher than that of the control group (P<0.05), and the macular fovea thickness of the observation group was significantly smaller than that of the control group (P<0.05). The incidence of complications in the observation group (3.36%) was significantly lower than that in the control group (10.92%, P<0.05). Conclusion: Anti VEGF drug Conbercept Ophthalmic combined with PRP is more effective than PRP alone in the treatment of DME patients with higher safety.